Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2020.10.080 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2020.10.080 33303190!7698684!33303190     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biochem+Biophys+Res+Commun 2021 ; 538 (ä): 80-87 Nephropedia Template TP {{tp|p=33303190|t=2021. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy |pdf=|usr=}}{{33303190}} gab.com Text The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33303190 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease-19), represents a far more serious threat to public health than SARS and MERS coronaviruses, due to its ability to spread more efficiently than its predecessors. Currently, there is no worldwide-approved effective treatment for COVID-19, urging the scientific community to intense efforts to accelerate the discovery and development of prophylactic and therapeutic solutions against SARS-CoV-2 infection. In particular, effective antiviral drugs are urgently needed. With few exceptions, therapeutic approaches to combat viral infections have traditionally focused on targeting unique viral components or enzymes; however, it has now become evident that this strategy often fails due to the rapid emergence of drug-resistant viruses. Targeting host factors that are essential for the virus life cycle, but are dispensable for the host, has recently received increasing attention. The spike glycoprotein, a component of the viral envelope that decorates the virion surface as a distinctive crown ("corona") and is essential for SARS-CoV-2 entry into host cells, represents a key target for developing therapeutics capable of blocking virus invasion. This review highlights aspects of the SARS-CoV-2 spike biogenesis that may be amenable to host-directed antiviral targeting. Twit Text FOAVip The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=33303190 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33303190 #FOAvip English Wikipedia <ref>{{Cite pmid|33303190}}</ref> The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy #MMPMID33303190 Santopolo S; Riccio A; Santoro MG Biochem Biophys Res Commun 2021[Jan]; 538 (ä): 80-87 PMID33303190show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease-19), represents a far more serious threat to public health than SARS and MERS coronaviruses, due to its ability to spread more efficiently than its predecessors. Currently, there is no worldwide-approved effective treatment for COVID-19, urging the scientific community to intense efforts to accelerate the discovery and development of prophylactic and therapeutic solutions against SARS-CoV-2 infection. In particular, effective antiviral drugs are urgently needed. With few exceptions, therapeutic approaches to combat viral infections have traditionally focused on targeting unique viral components or enzymes; however, it has now become evident that this strategy often fails due to the rapid emergence of drug-resistant viruses. Targeting host factors that are essential for the virus life cycle, but are dispensable for the host, has recently received increasing attention. The spike glycoprotein, a component of the viral envelope that decorates the virion surface as a distinctive crown ("corona") and is essential for SARS-CoV-2 entry into host cells, represents a key target for developing therapeutics capable of blocking virus invasion. This review highlights aspects of the SARS-CoV-2 spike biogenesis that may be amenable to host-directed antiviral targeting. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*pharmacology/therapeutic use[MESH] |COVID-19/virology[MESH] |Glycosylation[MESH] |Humans[MESH] |Molecular Targeted Therapy[MESH] |Protein Folding[MESH] |SARS-CoV-2/*drug effects/physiology[MESH] |Spike Glycoprotein, Coronavirus/*antagonists & inhibitors/*biosynthesis/chemistry[MESH]The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for (epmc).pdf DeepDyve Pubget Overpricing